Horizon Therapeutics Public Limited Company focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. More Details
+ 1 more risk
High growth potential with adequate balance sheet.
Share Price & News
How has Horizon Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: HZNP is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: HZNP's weekly volatility (7%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: HZNP exceeded the US Biotechs industry which returned 19.2% over the past year.
Return vs Market: HZNP exceeded the US Market which returned 49.4% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Horizon Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 days ago | Simply Wall StHorizon Therapeutics Public Limited Company's (NASDAQ:HZNP) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
2 weeks ago | Simply Wall StWe Think Shareholders Will Probably Be Generous With Horizon Therapeutics Public Limited Company's (NASDAQ:HZNP) CEO Compensation
1 month ago | Simply Wall StNeed To Know: Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) Insiders Have Been Selling Shares
Is Horizon Therapeutics undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: HZNP ($87.74) is trading below our estimate of fair value ($157.59)
Significantly Below Fair Value: HZNP is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: HZNP is poor value based on its PE Ratio (66.6x) compared to the US Biotechs industry average (25.7x).
PE vs Market: HZNP is poor value based on its PE Ratio (66.6x) compared to the US market (19.5x).
Price to Earnings Growth Ratio
PEG Ratio: HZNP is good value based on its PEG Ratio (0.9x)
Price to Book Ratio
PB vs Industry: HZNP is overvalued based on its PB Ratio (5.1x) compared to the US Biotechs industry average (3.3x).
How is Horizon Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 11 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: HZNP's forecast earnings growth (71.2% per year) is above the savings rate (2%).
Earnings vs Market: HZNP's earnings (71.2% per year) are forecast to grow faster than the US market (14.7% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: HZNP's revenue (14.8% per year) is forecast to grow faster than the US market (9% per year).
High Growth Revenue: HZNP's revenue (14.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: HZNP's Return on Equity is forecast to be high in 3 years time (30.7%)
How has Horizon Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: HZNP has a large one-off loss of $84.3M impacting its March 31 2021 financial results.
Growing Profit Margin: HZNP's current net profit margins (12.8%) are lower than last year (43.1%).
Past Earnings Growth Analysis
Earnings Trend: HZNP has become profitable over the past 5 years, growing earnings by 58.3% per year.
Accelerating Growth: HZNP's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: HZNP had negative earnings growth (-52.7%) over the past year, making it difficult to compare to the Biotechs industry average (1.6%).
Return on Equity
High ROE: HZNP's Return on Equity (7.3%) is considered low.
How is Horizon Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: HZNP's short term assets ($1.8B) exceed its short term liabilities ($773.8M).
Long Term Liabilities: HZNP's short term assets ($1.8B) do not cover its long term liabilities ($3.2B).
Debt to Equity History and Analysis
Debt Level: HZNP's debt to equity ratio (66.9%) is considered high.
Reducing Debt: HZNP's debt to equity ratio has reduced from 88.2% to 66.9% over the past 5 years.
Debt Coverage: HZNP's debt is well covered by operating cash flow (23.8%).
Interest Coverage: HZNP's interest payments on its debt are well covered by EBIT (7.6x coverage).
What is Horizon Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate HZNP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate HZNP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if HZNP's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if HZNP's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of HZNP's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Tim Walbert (53 yo)
Mr. Timothy P. Walbert, also known as Tim, has been the Chairman of the Board at Exicure, Inc. since April 2020 and has been its Independent Director since July 22, 2019. Mr. Walbert served as Lead Indepen...
CEO Compensation Analysis
Compensation vs Market: Tim's total compensation ($USD21.63M) is above average for companies of similar size in the US market ($USD11.15M).
Compensation vs Earnings: Tim's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
Experienced Management: HZNP's management team is seasoned and experienced (6 years average tenure).
Experienced Board: HZNP's board of directors are considered experienced (7.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: HZNP insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 17.8%.
Horizon Therapeutics Public Limited Company's company bio, employee growth, exchange listings and data sources
- Name: Horizon Therapeutics Public Limited Company
- Ticker: HZNP
- Exchange: NasdaqGS
- Founded: 2005
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$19.721b
- Shares outstanding: 224.77m
- Website: https://www.horizontherapeutics.com
Number of Employees
- Horizon Therapeutics Public Limited Company
- Connaught House
- 1st Floor
- Co. Dublin
Horizon Therapeutics Public Limited Company focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and int...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/05/13 23:46|
|End of Day Share Price||2021/05/13 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.